AstraZeneca (NASDAQ:AZN) Releases Earnings Results, Beats Expectations By $0.03 EPS

AstraZeneca (NASDAQ:AZN) announced its earnings results on Tuesday. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03, Zacks reports. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.41%. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.87 EPS.

AstraZeneca Stock Down 0.4 %

AstraZeneca stock traded down $0.25 during midday trading on Thursday, reaching $65.04. The stock had a trading volume of 9,762,939 shares, compared to its average volume of 5,263,518. The company has a fifty day moving average price of $75.79 and a two-hundred day moving average price of $78.38. The company has a market capitalization of $201.66 billion, a P/E ratio of 31.12, a PEG ratio of 1.21 and a beta of 0.47. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. AstraZeneca has a 12 month low of $60.47 and a 12 month high of $87.68.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of recent research reports. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. TD Cowen raised their target price on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.